Structure-based repurposing of FDA-approved drugs as TNF-α inhibitors
Research output: Journal Publications and Reviews › RGC 21 - Publication in refereed journal › peer-review
Author(s)
Detail(s)
Original language | English |
---|---|
Pages (from-to) | 765-768 |
Journal / Publication | ChemMedChem |
Volume | 6 |
Issue number | 5 |
Publication status | Published - 2 May 2011 |
Link(s)
Abstract
Old dogs, new tricks! We applied structure-based virtual screening methods to identify small-molecule inhibitors of tumor necrosis factor-α (TNF-α) from a database of 3000 US Food and Drug Administration (FDA)-approved drugs. Darifenacin (Enablex) and ezetimibe (Zetia) were identified as direct TNF-α inhibition, representing only the fifth and sixth examples of small-molecule TNF-α inhibitors. © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Research Area(s)
- Approved drugs, Drug discovery, Inhibitors, Tumor necrosis factor, Virtual screening
Citation Format(s)
Structure-based repurposing of FDA-approved drugs as TNF-α inhibitors. / Leung, Chung-Hang; Chan, Daniel Shiu-Hin; Kwan, Maria Hiu-Tung et al.
In: ChemMedChem, Vol. 6, No. 5, 02.05.2011, p. 765-768.
In: ChemMedChem, Vol. 6, No. 5, 02.05.2011, p. 765-768.
Research output: Journal Publications and Reviews › RGC 21 - Publication in refereed journal › peer-review